Fetal liver mesenchymal stem cells restore ovarian function in premature ovarian insufficiency by targeting MT1.

ABSTRACT: BACKGROUND:With the development of regenerative medicine and tissue engineering technology, almost all stem cell therapy is efficacious for the treatment of premature ovarian failure (POF) or premature ovarian insufficiency (POI) animal models, whereas little stem cell therapy has been practiced in clinical settings. The underlying molecular mechanism and safety of stem cell treatment in POI are not fully understood. In this study, we explored whether fetal mesenchymal stem cells (fMSCs) from the liver restore ovarian function and whether melatonin membrane receptor 1 (MT1) acts as a regulator for treating POI disease. METHODS:We designed an in vivo model (chemotherapy-induced ovary damage) and an in vitro model (human ovarian granulosa cells (hGCs)) to understand the efficacy and molecula

SUBMITTER: Huang B 

PROVIDER: S-EPMC6884777 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature